Humana Inc. (ETR:HUM)
| Market Cap | 50.33B +105.0% |
| Revenue (ttm) | 135.78B +22.0% |
| Net Income | 1.10B -3.5% |
| EPS | 9.35 -3.7% |
| Shares Out | n/a |
| PE Ratio | 44.49 |
| Forward PE | 26.63 |
| Dividend | 3.13 (0.75%) |
| Ex-Dividend Date | Dec 24, 2026 |
| Volume | 47 |
| Open | 410.00 |
| Previous Close | 400.00 |
| Day's Range | 406.00 - 420.00 |
| 52-Week Range | 298.00 - 420.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Humana
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and... [Read more]
Financial Performance
In 2025, Humana's revenue was $129.66 billion, an increase of 10.11% compared to the previous year's $117.76 billion. Earnings were $1.19 billion, a decrease of -1.57%.
Financial numbers in USD Financial StatementsNews
Humana Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced the expiration and final results of its previously announced cash tender offers (collectively, the ...
Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced the Reference Yield and Total Consideration (as set forth in the table below) to be paid in connect...
Monday's First Moves: GTA VI Presales Top $1B, TSN Earnings, HUM Upgrade
Grand Theft Auto 6 presales have officially topped $1 billion in what is poised to be the biggest video game debut ever. Diane King Hall talks about what the massive launch means for Take-Two Interact...
Humana upgraded to Outperform at RBC Capital on earnings potential
As previously reported, RBC Capital upgraded Humana (HUM) to Outperform from Sector Perform with a price target of $563, up from $415. The company’s “impressive” Stars turnaround, alongside discipline...
Humana upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Humana (HUM) to Outperform from Sector Perform with a price target of $563, up from $415.
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humana price target raised to $602 from $502 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Humana (HUM) to $602 from $502 and keeps an Overweight rating on the shares after the company beat Q3…
Humana price target raised to $430 from $370 at TD Cowen
TD Cowen raised the firm’s price target on Humana (HUM) to $430 from $370 and keeps a Hold rating on the shares. The firm updated its model following Q3 results…
Humana price target raised to $530 from $495 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Humana (HUM) to $530 from $495 and keeps an Outperform rating on the shares. The main takeover from the company’s…
Humana price target raised to $484 from $393 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Humana (HUM) to $484 from $393 and keeps a Neutral rating on the shares.
New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden
LOUISVILLE, Ky.--(BUSINESS WIRE)--New oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burden.
Humana price target raised to $516 from $436 at Deutsche Bank
Deutsche Bank analyst George Hill raised the firm’s price target on Humana (HUM) to $516 from $436 and keeps a Buy rating on the shares. The company reported better than…
Humana price target raised to $521 from $471 at Guggenheim
Guggenheim raised the firm’s price target on Humana (HUM) to $521 from $471 and keeps a Buy rating on the shares. Humana reported upside to Q3 EPS as favorable cost…
Humana Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced that it has commenced cash tender offers (collectively, the “Offers”) to purchase the outstanding n...
Humana price target raised to $526 from $463 at Piper Sandler
Piper Sandler raised the firm’s price target on Humana (HUM) to $526 from $463 and keeps an Overweight rating on the shares. The firm takes its 2027-2028 materially higher following…
Humana price target raised to $587 from $582 at Barclays
Barclays raised the firm’s price target on Humana (HUM) to $587 from $582 and keeps an Overweight rating on the shares.
Humana Earnings Call Transcript: Q3 2026
2026 adjusted EPS guidance rose to at least $9.50, with individual MA margins on track to double excluding the Stars headwind. Strong BY28 Stars results and early AEP indicators support the recovery, while higher 2027 cost trends remain a key consideration.
Humana Earnings release: Q3 2026
Humana released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
Humana Prepared remarks: Q3 2026
Humana filed a regulatory document on November 6, 2026 disclosing important business information.
Humana Quarterly report: Q3 2026
Humana has published its Q3 2026 quarterly earnings report on November 6, 2026.
Humana Lifts Outlook as Quarterly Revenue Jumps
Humana raised its full-year earnings outlook as consolidated income and revenue rose in the recent quarter.
Humana reports Q3 adjusted EPS (70c), consensus ($1.00)
Reports Q3 revenue $41.16B, consensus $40.89B. “Humana (HUM) is delivering positive results for our members, our patients and their health,” said Humana President and CEO Jim Rechtin. “We are also…
Humana raises FY26 adjusted EPS view to ‘at least’ $9.50 from ‘at least’ $9.00
FY26 consensus $9.16.
Humana Reports Third Quarter 2026 Financial Results; Raises Full Year 2026 Adjusted EPS Guidance
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share for the quarter ended September 30, 2026 (3Q26) versus the quarter e...